162 related articles for article (PubMed ID: 22621697)
1. MicroRNAs in the pathogenesis of malignant melanoma.
Glud M; Gniadecki R
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):142-50. PubMed ID: 22621697
[TBL] [Abstract][Full Text] [Related]
2. The genome and epigenome of malignant melanoma.
Dahl C; Guldberg P
APMIS; 2007 Oct; 115(10):1161-76. PubMed ID: 18042149
[TBL] [Abstract][Full Text] [Related]
3. Genes involved in melanoma: an overview of INK4a and other loci.
Castellano M; Parmiani G
Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
[TBL] [Abstract][Full Text] [Related]
4. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
J Invest Dermatol; 2010 Dec; 130(12):2809-17. PubMed ID: 20703244
[TBL] [Abstract][Full Text] [Related]
5. Signatures of microRNAs and selected microRNA target genes in human melanoma.
Philippidou D; Schmitt M; Moser D; Margue C; Nazarov PV; Muller A; Vallar L; Nashan D; Behrmann I; Kreis S
Cancer Res; 2010 May; 70(10):4163-73. PubMed ID: 20442294
[TBL] [Abstract][Full Text] [Related]
6. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
9. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
12. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
13. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
14. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
15. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
[TBL] [Abstract][Full Text] [Related]
16. [Molecular biology of familial cases of human melanoma].
Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
[TBL] [Abstract][Full Text] [Related]
17. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
18. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
Zhao Y; Zhang Y; Yang Z; Li A; Dong J
Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
